Benign Prostatic Hyperplasia Agents

PROSTIF

Finasteride is a drug for the treatment of Benign Prostatic Hyperplasia (BPH) commonly known as enlarged Prostate the condition in which size of prostate glands increases in middle-aged and old aged man.

It is proven to improve the symptoms associated with BPH such as difficulties related to urination such as getting up during the night to urinate, hesitation at the start of urination, and decreased urinary flow.

General Info

Generic Name:	Finasteride
Therapeutic Category:	Benign Prostatic Hyperplasia Agents
Pharmacological Class:	Type II 5 alpha-reductase inhibitor
Composition:	Each film coated tablet contains Finasteride USP 5 mg
Pregnancy Category:	X
Presentation:	Available in the pack size as 14 tablets X 2 blisters
Mechanism of Action:	PROSTIF works by forming a stable complex with the enzyme Type II 5a-reductase which results in inhibition of the enzyme Type II 5a-reductase is the enzyme necessary for peripheral conversion of testosterone to 5α-dihydrotestosterone (DHT) which is responsible for stimulation of prostatic growth. Hence inhibition of Type II 5a-reductase results in blockage of formation of DHT consequently decreasing its serum and tissue DHT concentrations by approximately 20-30% after continued therapy of more than 6 months.
Indications:	Treatment of symptomatic BPH Reduce the risk of the need for surgery including transurethral resection of Prostate (TURP) and prostatectomy. Reduce the risk of Acute Urinary Retention
Dosage :	Route of administration: Oral 5 mg orally once a day
Pharmacokinetics:	Absorption: N/A Protein binding: Approximately 90% Metabolism: Hepatic Route of elimination: 32-46% was excreted in the urine in the form of metabolites; 57% was excreted in the feces. Half-life: 4.5 hours
Adverse Effects:	Allergic reactions, including rash, itching, hives, and swelling of the lips and face Rarely, some men may have testicular pain Male infertility and/or poor quality of semen Improvement in the quality of semen has been reported after stopping the medication Decrease in sex drive that continued after stopping the medication enlarged or painful breast. promptly report to doctor any changes in breasts such as lumps, pain or discharge In rare cases, male breast cancer has been reported
Contraindications:	PROSTIF is contraindicated in the following populations and situations: Crushed or broken finasteride tablets should not be handled by women who are or may become pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus Children and people with known significant hypersensitivity (e.g., serious skin reactions, angioedema) to Finasteride should not take Finasteride.